private:milestonepharmaceuticals
|
5882207
|
May 30th, 2019 12:00AM
|
Milestone Pharmaceuticals, Inc.
|
1.1K
|
38.00
|
Open
|
Biotechnology
|
May 29th, 2019 08:10PM
|
May 29th, 2019 08:10PM
|
Milestone Pharmaceuticals Inc. is a cardiovascular drug development company developing novel small molecule therapeutics for transient cardiovascular conditions. Milestone's lead product is a potent and short-acting nasally-delivered calcium channel antagonist for the episodic treatment of paroxysmal supraventricular tachycardia (PSVT). The company's lead product, etripamil (MSP-2017), is in phase 3.
|
Open
|
|
Open
|
13850 Ballantyne Corporate Pl, Suite 500
|
Charlotte
|
North Carolina
|
US
|
28277
|
|
Milestone Pharmaceuticals
|
Health Care
|
Health Care Equipment & Services
|
private:milestonepharmaceuticals
|
5882207
|
Feb 17th, 2018 12:00AM
|
Milestone Pharmaceuticals, Inc.
|
181
|
14.00
|
Open
|
Biotechnology
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
Milestone Pharmaceuticals Inc. is a cardiovascular drug development company developing novel small molecule therapeutics for transient cardiovascular conditions. Milestone's lead product is a potent and short-acting nasally-delivered calcium channel antagonist for the episodic treatment of paroxysmal supraventricular tachycardia (PSVT). The company's lead product, etripamil (MSP-2017), is in phase 3.
|
|
|
|
|
|
|
|
|
|
Milestone Pharmaceuticals
|
Health Care
|
Health Care Equipment & Services
|
private:milestonepharmaceuticals
|
5882207
|
Feb 16th, 2018 12:00AM
|
Milestone Pharmaceuticals, Inc.
|
181
|
14.00
|
Open
|
Biotechnology
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
Milestone Pharmaceuticals Inc. is a cardiovascular drug development company developing novel small molecule therapeutics for transient cardiovascular conditions. Milestone's lead product is a potent and short-acting nasally-delivered calcium channel antagonist for the episodic treatment of paroxysmal supraventricular tachycardia (PSVT). The company's lead product, etripamil (MSP-2017), is in phase 3.
|
|
|
|
|
|
|
|
|
|
Milestone Pharmaceuticals
|
Health Care
|
Health Care Equipment & Services
|
private:milestonepharmaceuticals
|
5882207
|
Feb 15th, 2018 12:00AM
|
Milestone Pharmaceuticals, Inc.
|
181
|
14.00
|
Open
|
Biotechnology
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
Milestone Pharmaceuticals Inc. is a cardiovascular drug development company developing novel small molecule therapeutics for transient cardiovascular conditions. Milestone's lead product is a potent and short-acting nasally-delivered calcium channel antagonist for the episodic treatment of paroxysmal supraventricular tachycardia (PSVT). The company's lead product, etripamil (MSP-2017), is in phase 3.
|
|
|
|
|
|
|
|
|
|
Milestone Pharmaceuticals
|
Health Care
|
Health Care Equipment & Services
|
private:milestonepharmaceuticals
|
5882207
|
Feb 14th, 2018 12:00AM
|
Milestone Pharmaceuticals, Inc.
|
181
|
14.00
|
Open
|
Biotechnology
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
Milestone Pharmaceuticals Inc. is a cardiovascular drug development company developing novel small molecule therapeutics for transient cardiovascular conditions. Milestone's lead product is a potent and short-acting nasally-delivered calcium channel antagonist for the episodic treatment of paroxysmal supraventricular tachycardia (PSVT). The company's lead product, etripamil (MSP-2017), is in phase 3.
|
|
|
|
|
|
|
|
|
|
Milestone Pharmaceuticals
|
Health Care
|
Health Care Equipment & Services
|
private:milestonepharmaceuticals
|
5882207
|
Feb 13th, 2018 12:00AM
|
Milestone Pharmaceuticals, Inc.
|
181
|
14.00
|
Open
|
Biotechnology
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
Milestone Pharmaceuticals Inc. is a cardiovascular drug development company developing novel small molecule therapeutics for transient cardiovascular conditions. Milestone's lead product is a potent and short-acting nasally-delivered calcium channel antagonist for the episodic treatment of paroxysmal supraventricular tachycardia (PSVT). The company's lead product, etripamil (MSP-2017), is in phase 3.
|
|
|
|
|
|
|
|
|
|
Milestone Pharmaceuticals
|
Health Care
|
Health Care Equipment & Services
|
private:milestonepharmaceuticals
|
5882207
|
Feb 12th, 2018 12:00AM
|
Milestone Pharmaceuticals, Inc.
|
181
|
14.00
|
Open
|
Biotechnology
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
Milestone Pharmaceuticals Inc. is a cardiovascular drug development company developing novel small molecule therapeutics for transient cardiovascular conditions. Milestone's lead product is a potent and short-acting nasally-delivered calcium channel antagonist for the episodic treatment of paroxysmal supraventricular tachycardia (PSVT). The company's lead product, etripamil (MSP-2017), is in phase 3.
|
|
|
|
|
|
|
|
|
|
Milestone Pharmaceuticals
|
Health Care
|
Health Care Equipment & Services
|
private:milestonepharmaceuticals
|
5882207
|
Feb 11th, 2018 12:00AM
|
Milestone Pharmaceuticals, Inc.
|
181
|
14.00
|
Open
|
Biotechnology
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
Milestone Pharmaceuticals Inc. is a cardiovascular drug development company developing novel small molecule therapeutics for transient cardiovascular conditions. Milestone's lead product is a potent and short-acting nasally-delivered calcium channel antagonist for the episodic treatment of paroxysmal supraventricular tachycardia (PSVT). The company's lead product, etripamil (MSP-2017), is in phase 3.
|
|
|
|
|
|
|
|
|
|
Milestone Pharmaceuticals
|
Health Care
|
Health Care Equipment & Services
|
private:milestonepharmaceuticals
|
5882207
|
Feb 10th, 2018 12:00AM
|
Milestone Pharmaceuticals, Inc.
|
181
|
14.00
|
Open
|
Biotechnology
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
Milestone Pharmaceuticals Inc. is a cardiovascular drug development company developing novel small molecule therapeutics for transient cardiovascular conditions. Milestone's lead product is a potent and short-acting nasally-delivered calcium channel antagonist for the episodic treatment of paroxysmal supraventricular tachycardia (PSVT). The company's lead product, etripamil (MSP-2017), is in phase 3.
|
|
|
|
|
|
|
|
|
|
Milestone Pharmaceuticals
|
Health Care
|
Health Care Equipment & Services
|
private:milestonepharmaceuticals
|
5882207
|
Feb 9th, 2018 12:00AM
|
Milestone Pharmaceuticals, Inc.
|
181
|
14.00
|
Open
|
Biotechnology
|
Feb 9th, 2017 08:57AM
|
Feb 9th, 2017 08:57AM
|
Milestone Pharmaceuticals Inc. is a cardiovascular drug development company developing novel small molecule therapeutics for transient cardiovascular conditions. Milestone's lead product is a potent and short-acting nasally-delivered calcium channel antagonist for the episodic treatment of paroxysmal supraventricular tachycardia (PSVT). The company's lead product, etripamil (MSP-2017), is in phase 3.
|
|
|
|
|
|
|
|
|
|
Milestone Pharmaceuticals
|
Health Care
|
Health Care Equipment & Services
|